FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891625981> ?p ?o ?g. }

• W2891625981 endingPage "121" @default.
• W2891625981 startingPage "112" @default.
• W2891625981 abstract "Approximately, 20% of patients with pancreatic ductal adenocarcinoma have resectable disease at diagnosis. Given improvements in locoregional and systemic therapies, some patients with borderline resectable pancreatic cancer (BRPC) can now undergo successful resection. The outcomes of patients with BRPC after neoadjuvant therapy remain unclear. A prospectively maintained single-institution database was utilized to identify patients with BRPC who were managed at the Johns Hopkins Pancreas Multidisciplinary Clinic (PMDC) between 2013 and 2016. BRPC was defined as any tumor that presented with radiographic evidence of the involvement of the portal vein (PV) or superior mesenteric vein (SMV) that was deemed to be technically resectable (with or without the need for reconstruction), or the abutment (< 180° involvement) of the common hepatic artery (CHA) or superior mesenteric artery (SMA), in the absence of involvement of the celiac axis (CA). We collected data on treatment, the course of the disease, resection rate, and survival. Of the 866 patients evaluated at the PMDC during the study period, 151 (17.5%) were staged as BRPC. Ninety-six patients (63.6%) underwent resection. Neoadjuvant chemotherapy was administered to 142 patients (94.0%), while 78 patients (51.7%) received radiation therapy in the neoadjuvant setting. The median overall survival from the date of diagnosis, of resected BRPC patients, was 28.8 months compared to 14.5 months in those who did not (p < 0.001). Factors associated with increased chance of surgical resection included lower ECOG performance status (p = 0.011) and neck location of the tumor (p = 0.001). Forty-seven patients with BRPC (31.1%) demonstrated progression of disease; surgical resection was attempted and aborted in 12 patients (7.9%). Eight patients (5.3%) were unable to tolerate chemotherapy; six had disease progression and two did not want to pursue surgery. Lastly, four patients (3.3%) were conditionally unresectable due to medical comorbidities at the time of diagnosis due to comorbidities and failed to improve their status and subsequently had progression of the disease. After initial management, 31.1% of patients with BRPC have progression of disease, while 63.6% of all patients successfully undergo resection, which was associated with improved survival. Factors associated with increased likelihood of surgical resection include lower ECOG performance status and tumor location in the neck." @default.
• W2891625981 created "2018-09-27" @default.
• W2891625981 creator A5004066994 @default.
• W2891625981 creator A5013429820 @default.
• W2891625981 creator A5014748431 @default.
• W2891625981 creator A5021639465 @default.
• W2891625981 creator A5026919131 @default.
• W2891625981 creator A5029871629 @default.
• W2891625981 creator A5033720986 @default.
• W2891625981 creator A5039843730 @default.
• W2891625981 creator A5051619233 @default.
• W2891625981 creator A5060335470 @default.
• W2891625981 creator A5070188771 @default.
• W2891625981 creator A5077513821 @default.
• W2891625981 creator A5078198832 @default.
• W2891625981 creator A5086998230 @default.
• W2891625981 creator A5089299130 @default.
• W2891625981 date "2018-09-21" @default.
• W2891625981 modified "2023-10-06" @default.
• W2891625981 title "Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy" @default.
• W2891625981 cites W1987814657 @default.
• W2891625981 cites W1992458280 @default.
• W2891625981 cites W1994177577 @default.
• W2891625981 cites W2012005360 @default.
• W2891625981 cites W2015083350 @default.
• W2891625981 cites W2044211072 @default.
• W2891625981 cites W2050575833 @default.
• W2891625981 cites W2054625398 @default.
• W2891625981 cites W2117009632 @default.
• W2891625981 cites W2160391606 @default.
• W2891625981 cites W2166202366 @default.
• W2891625981 cites W2171950337 @default.
• W2891625981 cites W2267469086 @default.
• W2891625981 cites W2409856225 @default.
• W2891625981 cites W2698863275 @default.
• W2891625981 cites W2704847293 @default.
• W2891625981 cites W2737789729 @default.
• W2891625981 cites W2743061229 @default.
• W2891625981 cites W2748946473 @default.
• W2891625981 cites W2761846603 @default.
• W2891625981 cites W2764210227 @default.
• W2891625981 cites W2765938006 @default.
• W2891625981 cites W2770835903 @default.
• W2891625981 cites W2781525129 @default.
• W2891625981 cites W2788490210 @default.
• W2891625981 cites W2790680781 @default.
• W2891625981 cites W2793310755 @default.
• W2891625981 cites W2801301689 @default.
• W2891625981 cites W2801588121 @default.
• W2891625981 cites W2912196744 @default.
• W2891625981 doi "https://doi.org/10.1007/s11605-018-3966-8" @default.
• W2891625981 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6329638" @default.
• W2891625981 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30242644" @default.
• W2891625981 hasPublicationYear "2018" @default.
• W2891625981 type Work @default.
• W2891625981 sameAs 2891625981 @default.
• W2891625981 citedByCount "49" @default.
• W2891625981 countsByYear W28916259812019 @default.
• W2891625981 countsByYear W28916259812020 @default.
• W2891625981 countsByYear W28916259812021 @default.
• W2891625981 countsByYear W28916259812022 @default.
• W2891625981 countsByYear W28916259812023 @default.
• W2891625981 crossrefType "journal-article" @default.
• W2891625981 hasAuthorship W2891625981A5004066994 @default.
• W2891625981 hasAuthorship W2891625981A5013429820 @default.
• W2891625981 hasAuthorship W2891625981A5014748431 @default.
• W2891625981 hasAuthorship W2891625981A5021639465 @default.
• W2891625981 hasAuthorship W2891625981A5026919131 @default.
• W2891625981 hasAuthorship W2891625981A5029871629 @default.
• W2891625981 hasAuthorship W2891625981A5033720986 @default.
• W2891625981 hasAuthorship W2891625981A5039843730 @default.
• W2891625981 hasAuthorship W2891625981A5051619233 @default.
• W2891625981 hasAuthorship W2891625981A5060335470 @default.
• W2891625981 hasAuthorship W2891625981A5070188771 @default.
• W2891625981 hasAuthorship W2891625981A5077513821 @default.
• W2891625981 hasAuthorship W2891625981A5078198832 @default.
• W2891625981 hasAuthorship W2891625981A5086998230 @default.
• W2891625981 hasAuthorship W2891625981A5089299130 @default.
• W2891625981 hasBestOaLocation W28916259812 @default.
• W2891625981 hasConcept C121608353 @default.
• W2891625981 hasConcept C126322002 @default.
• W2891625981 hasConcept C126838900 @default.
• W2891625981 hasConcept C141071460 @default.
• W2891625981 hasConcept C2776390723 @default.
• W2891625981 hasConcept C2776694085 @default.
• W2891625981 hasConcept C2776820930 @default.
• W2891625981 hasConcept C2777575454 @default.
• W2891625981 hasConcept C2778292576 @default.
• W2891625981 hasConcept C2778764654 @default.
• W2891625981 hasConcept C2779033008 @default.
• W2891625981 hasConcept C2780210213 @default.
• W2891625981 hasConcept C2781046184 @default.
• W2891625981 hasConcept C530470458 @default.
• W2891625981 hasConcept C71924100 @default.
• W2891625981 hasConceptScore W2891625981C121608353 @default.
• W2891625981 hasConceptScore W2891625981C126322002 @default.
• W2891625981 hasConceptScore W2891625981C126838900 @default.
• W2891625981 hasConceptScore W2891625981C141071460 @default.

• next